conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research
estim
price data
rate updat
currenc amount express
methodolog valu compani
conduct deeper dive competit
dynam alexion face lower fair valu
estim put share territori
march think market underappreci
alexion invalu rare-diseas expertis network
patient doctor pose high barrier entri
brand competitor compani narrow moat
underpin intang asset includ patent
protect orphan drug exclus rare-diseas
portfolio incorpor price headwind like
competitor entri model off-set strong volum
growth recent approv gener myasthenia gravi
gmg neuromyel optica spectrum disord
nmosd approv
think alexion smartli price ultomiri
approv decemb offer
conveni dose schedul six seven time per year
compar soliri infus per year
offer slight discount soliri
averag net annual price estim
compani abl effici convert patient
ultomiri allow alexion maintain share even
biosimilar potenti brand competitor encroach
despit outsiz success soliri last decad
alexion come turbul year
expens acquisit investig
aggress sell tactic nearli complet
manag turnov plu restructur believ
alexion final side seriou
misstep execut previou manag
new leadership record larg unprov strong
launch gmg approv ultomiri recent
promis early-stag acquisit point new era
beleagu biotech
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
analyst note adjust net incom includ adjust differ non-gaap share
special develop market drug
rare life-threaten medic condit blockbust product soliri
approv paroxysm nocturn hemoglobinuria atyp hemolyt
urem syndrom gener myasthenia gravi next-gener
ultomiri recent approv paroxysm nocturn hemoglobinuria
strensiq kanuma target ultrarar metabol diseas alexion
rare diseas high unmet need
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
downgrad compani moat trend stabl
neg take account upcom patent
expir soliri wherea alexion narrow
moat cement clear patent protect
think forthcom like biosimilar hit price
pressur indic alexion competit posit
precari next five year compar
past sever year said patent-protect
ultomiri peak sale billion label
expans orphan drug indic gmg approv
nmosd approv help compani earn return
cost capit throughout explicit forecast
see sever potenti catalyst year ahead
includ roll-out ultomiri began januari
potenti approv soliri nmosd
trial readout pipelin candid look
forward detail pipelin compani
investor day later month well updat
ultomiri launch pipelin rel early-
stage contribut modestli valuat
success futur readout could provid upsid fair
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
